Zilver Vena静脉支架治疗症状性髂股静脉流出道梗阻的12个月终点结果:VIVO临床研究
VIVO是一项前瞻性、非随机、多中心研究,纳入243例症状性单侧髂股静脉段梗阻患者,置入Zilver Vena自膨式静脉支架。30天主要不良事件免除率为96.7%,12个月原发定量通畅率为89.9%,均优于文献定义的性能目标;VCSS从基线至12个月变化为-4.2,症状显著改善。
要点
- 30天主要不良事件免除率96.7%,优于文献定义性能目标87%(P<.0001)。
- 12个月原发定量通畅率89.9%,优于文献定义性能目标76%(P<.0001)。
- VCSS从基线至12个月变化为-4.2(95%CI -4.7至-3.7,P<.0001),症状改善。
核心结论
- VIVO研究12个月结果表明,Zilver Vena静脉支架治疗症状性髂股静脉流出道梗阻安全有效,包括临床症状较基线改善。
研究设计与样本
- VIVO临床研究为前瞻性、非随机、多中心研究,纳入症状性单侧髂股静脉段梗阻患者,CEAP临床分级≥3或VCSS疼痛评分≥2,所有患者接受Zilver Vena自膨式静脉支架(Cook Ireland Ltd,Limerick,爱尔兰)治疗。
- 2013年12月至2016年10月期间,在30家机构共纳入243例患者(女性70%;平均年龄53±15岁;67.5%有当前或既往深静脉血栓)。
主要发现
- 髂动脉压迫髂静脉是支架置入的主要指征(n=191;78.6%),平均病变长度为98.6±69.8 mm。
- 30天主要不良事件免除率为96.7%,高于文献定义的性能目标87%(95%CI 93.5%-98.6%;P<.0001)。
- 12个月原发定量通畅率为89.9%,高于文献定义的性能目标76%(95%CI 85.1%-93.4%;P<.0001)。
- VCSS从基线变化:1个月为-3.0(95%CI -3.5至-2.6;P<.0001),12个月为-4.2(95%CI -4.7至-3.7;P<.0001)。
- 12个月临床驱动再干预免除率为95.8%±1.3%;至12个月无支架断裂,发生1例临床迁移(临床事件委员会裁定为置入时器械尺寸不足所致的技术相关事件)。
关键数值与推荐
- 主要安全终点为30天主要不良事件免除率,主要有效性终点为核心实验室判定的12个月静脉造影原发定量通畅率。
- 次要终点为VCSS从基线至1个月和12个月的变化;其他指标包括临床驱动再干预免除率、CEAP C分级、VDS和CIVIQ评分从基线至12个月的变化及支架耐久性指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the present study, we evaluated the safety and effectiveness of the Zilver Vena venous stent in the treatment of patients with symptomatic iliofemoral outflow obstruction. METHODS: The VIVO clinical study was a prospective, nonrandomized, multicenter study that enrolled patients with symptomatic obstruction of one iliofemoral venous segment. Included were patients with Clinical, Etiological, Anatomical, Pathophysiological (CEAP) clinical classification of ≥3 or a Venous Clinical Severity Score (VCSS) pain score of ≥2. All patients received a self-expanding venous stent (Zilver Vena venous stent; Cook Ireland Ltd, Limerick, Ireland). The primary safety end point was 30-day freedom from major adverse events. The primary effectiveness end point was the 12-month rate of primary quantitative patency by venography as determined by the core laboratory. The secondary end point was the change in the VCSS from baseline to 1 and 12 months. Additional measures included freedom from clinically driven reintervention; change in the CEAP C classification, Venous Disability Score (VDS), and Chronic Venous Disease Quality of Life Questionnaire (CIVIQ) scores from baseline to 12 months; and stent durability measures. RESULTS: Between December 2013 and October 2016, 243 patients (70% female; mean age, 53 ± 15 years; 67.5% with current or previous deep vein thrombosis) were enrolled at 30 institutions. Iliac vein compression by the iliac artery (n = 191; 78.6%) was the primary indication for stent placement. The mean lesion length was 98.6 ± 69.8 mm. The 30-day freedom from major adverse events rate was 96.7%, greater than the literature-defined performance goal of 87% (95% confidence interval [CI], 93.5%-98.6%; P < .0001). The 12-month primary quantitative patency rate was 89.9%, greater than the literature-defined performance goal of 76% (95% CI, 85.1%-93.4%; P < .0001). The change in the VCSS from baseline was -3.0 (95% CI, -3.5 to -2.6; P < .0001) at 1 month and -4.2 (95% CI, -4.7 to -3.7; P < .0001) at 12 months, demonstrating clinical improvement. Similarly, significantly (P < .0001) fewer symptoms over time (from preprocedure through 12 months) were measured using the clinical measures of VDS, CEAP C classification, and CIVIQ. The 12-month rate of freedom from clinically driven reintervention was 95.8% ± 1.3%. Through 12 months, no stent fractures and one clinical migration (Clinical Events Committee adjudicated the latter as technique-related due to device undersizing at placement) had occurred. CONCLUSIONS: The 12-month results of the VIVO study have demonstrated the safety and effectiveness of the Zilver Vena venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction, including clinical symptom improvement compared with baseline.
引用
- Hofmann LR, Gagne P, Brown JA, et al. Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study). J Vasc Surg Venous Lymphat Disord. 2023. PMID: 36646383. doi:10.1016/j.jvsv.2022.12.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。